Francesco MD - Adicet Bio Chief VP

ACET Stock

USD 0.91 0.06 6.19%

Insider

Francesco MD is Chief VP of Adicet Bio

Age	56
Phone	650 503 9095
Web	https://www.adicetbio.com

Adicet Bio Management Efficiency

The company has return on total asset (ROA) of (0.293) % which means that it has lost $0.293 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5791) %, meaning that it created substantial loss on money invested by shareholders. Adicet Bio's management efficiency ratios could be used to measure how well Adicet Bio manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Adicet Bio to Peers

Predict price of Adicet Bio

Adicet Bio currently holds 20.92 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Adicet Bio has a current ratio of 15.78, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Adicet Bio's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Jeffrey Trigilio	Cullinan Oncology LLC	40
	Jacquelyn JD	Cullinan Oncology LLC	46
	Dean MD	Pliant Therapeutics	N/A
	Kevin MBA	Bicycle Therapeutics	56
	Marcy Graham	Aadi Bioscience	57
	Gillian Langford	Bicycle Therapeutics	N/A
	Johannes Hull	Pliant Therapeutics	49
	Behrad Derakhshan	Edgewise Therapeutics	44
	Benjamin Dake	Aerovate Therapeutics	48
	Jasbir Seehra	Keros Therapeutics	68
	Bruce Keyt	IGM Biosciences	71
	Sharon Townson	Monte Rosa Therapeutics	49
	Kristina Masson	Acrivon Therapeutics, Common	44
	Marc MD	Alector	50
	Christopher MSc	Keros Therapeutics	50
	MBA MD	Cullinan Oncology LLC	51
	MD FACP	Aadi Bioscience	74
	Tirtha Chakraborty	Vor Biopharma	51
	FACC MD	Stoke Therapeutics	61
	Suzette Tauber	IGM Biosciences	60
	Corinne Savill	Cullinan Oncology LLC	65

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 86 people. Adicet Bio (ACET) is traded on NASDAQ Exchange in USA. It is located in 131 Dartmouth Street, Boston, MA, United States, 02116 and employs 143 people. Adicet Bio is listed under Pharmaceutical Products category by Fama And French industry classification.

Management Performance

	Return On Equity	-0.58
	Return On Asset	-0.29

Adicet Bio Leadership Team

Elected by the shareholders, the Adicet Bio's board of directors comprises two types of representatives: Adicet Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Adicet. The board's role is to monitor Adicet Bio's management team and ensure that shareholders' interests are well served. Adicet Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Adicet Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Francesco MD, Chief VP
	BA CPA, Pres CEO
	Blake Aftab, Senior Officer
	Donald Healey, Chief Officer
	Amy Locke, Head Resources
	Brian Harvey, Chief Officer
	Aya Jakobovits, Founder Director

Adicet Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Adicet Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-0.58
	Return On Asset	-0.29
	Current Valuation	(104.18 M)
	Shares Outstanding	82.4 M
	Shares Owned By Insiders	1.59 %
	Shares Owned By Institutions	76.43 %
	Number Of Shares Shorted	3.44 M
	Price To Earning	36.84 X
	Price To Book	0.38 X
	Price To Sales	9.72 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Adicet Stock Analysis

When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC